Compare Aptiv PLC (APTV) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Crispr Therapeutics AG — how do they compare? Aptiv PLC trades at $50.3 (market cap $10.30B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Aptiv PLC is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | CRSP | |
|---|---|---|
Market Cap | $10.30B | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $76.78 |
52-Week Low | $46.30 | $44.34 |
Enterprise Value | $15.23B | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
